109 related articles for article (PubMed ID: 14981100)
21. Surgical risk-reduction in carriers of BRCA mutations: where do we go from here?
Kauff ND; Barakat RR
Gynecol Oncol; 2004 May; 93(2):277-9. PubMed ID: 15099933
[No Abstract] [Full Text] [Related]
22. Surgical risk reduction: prophylactic salpingo-oophorectomy and prophylactic mastectomy.
Dowdy SC; Stefanek M; Hartmann LC
Am J Obstet Gynecol; 2004 Oct; 191(4):1113-23. PubMed ID: 15507929
[TBL] [Abstract][Full Text] [Related]
23. Management problems. BRCA mutation, prophylactic oophorectomy and HRT.
Pines A
Climacteric; 1998 Dec; 1(4):309-10. PubMed ID: 11907939
[No Abstract] [Full Text] [Related]
24. Prophylactic surgery in patients with inherited risk of ovarian cancer.
Morice P; Pautier P; Delaloge S
Gynecol Oncol; 2001 Nov; 83(2):445-7. PubMed ID: 11606116
[No Abstract] [Full Text] [Related]
25. Ovary removal reduces cancer risk for BRCA1/2 carriers.
Health News; 2006 Oct; 12(10):6-7. PubMed ID: 17162794
[No Abstract] [Full Text] [Related]
26. Hormone replacement therapy and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers.
Kotsopoulos J; Lubinski J; Neuhausen SL; Lynch HT; Rosen B; Ainsworth P; Moller P; Ghadirian P; Isaacs C; Karlan B; Sun P; Narod SA
Gynecol Oncol; 2006 Jan; 100(1):83-8. PubMed ID: 16137751
[TBL] [Abstract][Full Text] [Related]
27. Additional salpingectomy after previous prophylactic oophorectomy in high-risk women: sense or nonsense?
Olivier RI; Lubsen-Brandsma LA; van Boven H; van Beurden M
Gynecol Oncol; 2005 Feb; 96(2):439-43. PubMed ID: 15661233
[TBL] [Abstract][Full Text] [Related]
28. Strategies for ovarian cancer prevention.
Dann RB; Kelley JL; Zorn KK
Obstet Gynecol Clin North Am; 2007 Dec; 34(4):667-86, viii. PubMed ID: 18061863
[TBL] [Abstract][Full Text] [Related]
29. Ovarian pathology in risk-reducing salpingo-oophorectomies from women with BRCA mutations, emphasizing the differential diagnosis of occult primary and metastatic carcinoma.
Rabban JT; Barnes M; Chen LM; Powell CB; Crawford B; Zaloudek CJ
Am J Surg Pathol; 2009 Aug; 33(8):1125-36. PubMed ID: 19440148
[TBL] [Abstract][Full Text] [Related]
30. The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers.
Metcalfe KA; Lynch HT; Ghadirian P; Tung N; Olivotto IA; Foulkes WD; Warner E; Olopade O; Eisen A; Weber B; McLennan J; Sun P; Narod SA
Gynecol Oncol; 2005 Jan; 96(1):222-6. PubMed ID: 15589605
[TBL] [Abstract][Full Text] [Related]
31. Prophylactic bilateral salpingo-oophorectomy compared with surveillance in women with BRCA mutations.
Schmeler KM; Sun CC; Bodurka DC; White KG; Soliman PT; Uyei AR; Erlichman JL; Arun BK; Daniels MS; Rimes SA; Peterson SK; Slomovitz BM; Milam MR; Gershenson DM; Lu KH
Obstet Gynecol; 2006 Sep; 108(3 Pt 1):515-20. PubMed ID: 16946209
[TBL] [Abstract][Full Text] [Related]
32. Does retention of the ovaries improve long-term survival after hysterectomy? Prophylactic oophorectomy.
Studd J
Climacteric; 2006 Jun; 9(3):164-6. PubMed ID: 16766429
[TBL] [Abstract][Full Text] [Related]
33. The average cumulative risks of breast and ovarian cancer for carriers of mutations in BRCA1 and BRCA2 attending genetic counseling units in Spain.
Milne RL; Osorio A; Cajal TR; Vega A; Llort G; de la Hoya M; Díez O; Alonso MC; Lazaro C; Blanco I; Sánchez-de-Abajo A; Caldés T; Blanco A; Graña B; Durán M; Velasco E; Chirivella I; Cardeñosa EE; Tejada MI; Beristain E; Miramar MD; Calvo MT; Martínez E; Guillén C; Salazar R; San Román C; Antoniou AC; Urioste M; Benítez J
Clin Cancer Res; 2008 May; 14(9):2861-9. PubMed ID: 18451254
[TBL] [Abstract][Full Text] [Related]
34. Risk-reducing salpingo-oophorectomy in patients with germline mutations in BRCA1 or BRCA2.
Kauff ND; Barakat RR
J Clin Oncol; 2007 Jul; 25(20):2921-7. PubMed ID: 17617523
[TBL] [Abstract][Full Text] [Related]
35. Hereditary breast and ovarian cancer syndrome.
ACOG Committee on Practice Bulletins
Gynecol Oncol; 2009 Apr; 113(1):6-11. PubMed ID: 19309638
[No Abstract] [Full Text] [Related]
36. Using genetic analysis to individualize preventive measures for breast and ovarian cancers.
Olopade OI
Nat Clin Pract Oncol; 2006 Apr; 3(4):182-3. PubMed ID: 16596140
[No Abstract] [Full Text] [Related]
37. Surgical management of BRCA1 and BRCA2 carriers: bitter choices slightly sweetened.
Rubinstein WS
J Clin Oncol; 2005 Nov; 23(31):7772-4. PubMed ID: 16219930
[No Abstract] [Full Text] [Related]
38. Unraveling the next chapter: sexual development, body image, and sexual functioning in female BRCA carriers.
Matloff ET; Barnett RE; Bober SL
Cancer J; 2009; 15(1):15-8. PubMed ID: 19197168
[TBL] [Abstract][Full Text] [Related]
39. BRCA1 genetic mutation and its link to ovarian cancer: implications for advanced practice nurses.
Brunsvold AN; Wung SF; Merkle CJ
J Am Acad Nurse Pract; 2005 Dec; 17(12):518-26. PubMed ID: 16293160
[TBL] [Abstract][Full Text] [Related]
40. [In familial breast or ovarian carcinoma: normal cancer prevention is not enough].
Riem L
MMW Fortschr Med; 2004 Apr; 146(15):12. PubMed ID: 15373015
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
